Novo Nordisk, Ypsomed and CagriSema
The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...
Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...
As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...
With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...
LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing ...
JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The firm’s analysis suggests CagriSema is likely to deliver 25% ...
LONDON (Reuters) -Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback